Moderna slips

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.
Moderna downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance
Goldman Sachs Downgrades Moderna (MRNA)
Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to Neutral. Analyst Price Forecast Suggests 57.38% Upside As of January 28, 2025, the average one-year price target for Moderna is $70.
Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Why Moderna (MRNA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Yahoo Finance17d
China's $1T trade surplus, Moderna stock slips: Morning Brief
Major banks will launch first-quarter earnings season this week, with reports from Citigroup (C), JPMorgan Chase (JPM), Goldman Sachs (GS), Wells Fargo (WFC), Bank of America (BAC), and Morgan ...
Morningstar14d
Goldman Sachs BDC, Inc. Schedules Earnings Release and Conference Call to Announce Fourth Quarter and Fiscal Year Ended 2024 Results
Goldman Sachs BDC, Inc. (“GS BDC”) (NYSE: GSBD) announced today that it will report its fourth quarter and fiscal year ended December 31, 2024 financial results after the market closes on ...
Meet the future leaders of Goldman Sachs' investment bank
Inside the careers, accomplishments, and clients of Goldman's new heads of investment banking: Kim Posnett, Matt McClure, and ...